| New from NCI |
| Making Cervical Cancer a Thing of the Past |
 |
|
Learn how Drs. Doug Lowy and John Schiller developed the human papillomavirus (HPV) vaccine, which can prevent 90% of HPV-related cancers, including cervical cancer. Also, read the story of Dr. Vikrant Sahasrabuddhe who wants to increase cervical cancer screening rates by proving that self-sampling for HPV is as good as screening done in a clinical setting. |
| Coronavirus Vaccines and People with Cancer |
 |
|
People with cancer and their caregivers still have questions about COVID-19 vaccines. This story from February 10, 2021, has been updated to answer common questions NCI's Cancer Information Service gets about COVID-19 vaccines and people with cancer. |
| Researchers Create Modified Antibodies to Target RAS and p53 in Cancer |
 |
|
Researchers have come up with a clever way to target RAS and p53, two of the most common proteins linked to cancer. In a series of studies, the scientists designed antibodies that shrank tumors in mice with these mutant proteins. |
Immunotherapy Drug Improves Survival in Children with Relapsed Leukemia
The immunotherapy drug blinatumomab (Blincyto) works better than chemotherapy in treating B-cell acute lymphoblastic leukemia that has relapsed in children and young adults. |
Whole-Genome Sequencing Could Help Guide AML Treatment
For people with acute myeloid leukemia (AML) and related cancers, a new study shows whole-genome sequencing could replace a series of tests usually used to help guide decisions about treatment.
|
| PDQ Updates |
Cancer Prevention Overview
We’ve revised this summary with updated information about the role of aspirin use and how it is not shown to prevent most cancers. |
Cigarette Smoking: Health Risks and How to Quit
We’ve added information about the rate of cigarette smoking among high school students dropping from 20% to 30% during the early 1990s to 6% by 2019. |
| FDA Approvals |
Tivozanib Hydrochloride
We’ve added a new drug summary for tivozanib hydrochloride (Fotivda), which the Food and Drug Administration recently approved to treat advanced kidney cancer that has been treated with two or more types of systemic therapy and has come back or did not respond to treatment. |
